HLF HERBALIFE LTD.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1180262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.4%
TTM net income YoY-44.0%
TTM EPS YoY-45.7%
Revenue 3-yr CAGR1.6%
Net income 3-yr CAGR-1.2%
Margins
Gross margin77.6%
Operating margin9.6%
Net margin3.4%
FCF margin6.4%
EBITDA margin11.9%
Returns
ROE—
ROA6.4%
ROIC (approx.)33.3%
Asset turnover1.89x
Leverage & solvency
Liabilities / assets114.0%
Debt / equity—
Current ratio1.19x
Interest coverage2.90x
Cash quality & payout
Operating cash flow / net income2.20x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.04B | $4.99B |
| Cost of revenue | $1.11B | $1.10B |
| Gross profit | $3.92B | $3.89B |
| SG&A expense | $1.66B | $1.73B |
| Operating income | $481.00M | $385.90M |
| Interest expense | $214.40M | $218.30M |
| Pretax income | $275.10M | $169.40M |
| Income tax | $47.30M | -$84.90M |
| Net income | $228.30M | $254.30M |
| EBITDA | $602.20M | $507.30M |
| EPS (basic) | 2.22 | 2.53 |
| EPS (diluted) | 2.20 | 2.50 |
| Weighted avg. shares (diluted) | 103.60M | 101.60M |
| Balance sheet | ||
| Cash & equivalents | $353.10M | $438.10M |
| Receivables | $91.90M | $68.90M |
| Inventory | $511.70M | $475.40M |
| Current assets | $1.14B | $1.14B |
| PP&E, net | $447.70M | $460.20M |
| Goodwill | $100.50M | $87.70M |
| Intangibles | $315.10M | $312.30M |
| Total assets | $2.79B | $2.73B |
| Current liabilities | $1.01B | $1.23B |
| Short-term debt | $20.90M | $283.50M |
| Long-term debt | $1.97B | $1.98B |
| Total debt | $1.99B | $2.26B |
| Total liabilities | $3.30B | $3.53B |
| Shareholders' equity | -$515.10M | -$801.10M |
| Net debt | $1.64B | $1.82B |
| Shares outstanding | 103.30M | 101.20M |
| Cash flow statement | ||
| Operating cash flow | $333.30M | $285.40M |
| Capital expenditure | $80.40M | $122.00M |
| Free cash flow | $252.90M | $163.40M |
| Investing cash flow | -$108.70M | -$84.60M |
| Financing cash flow | -$295.50M | -$335.30M |
| Depreciation & amortization | $121.20M | $121.40M |
| Stock-based compensation | $44.10M | $50.00M |
| Share buybacks | $8.20M | $8.30M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.